Exelixis, Inc. (EXEL) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1153917,
    "name": "Exelixis, Inc.",
    "stock_name": "Exelixis, Inc.",
    "full_name": "Exelixis, Inc.",
    "name_url": "stocks-analysis/exelixis-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "44.37",
    "chg": 0.93,
    "chgp": "2.14%",
    "dir": 1,
    "prev_price": "43.44",
    "mcapval": "10,146.24",
    "mcap": "Small Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US30161Q1040",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "4.11 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/exelixis-inc-1153917-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Exelixis, Inc. Experiences Revision in Its Stock Evaluation Amid Strong Performance Metrics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/exelixis-inc-sees-valuation-grade-downgrade-from-attractive-to-fair-amid-stock-decline-3667041",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/ExelixisInc_valuationdot_3667041.png",
        "date": "2025-11-03 15:38:29",
        "description": "Exelixis, Inc. has recently adjusted its valuation, showcasing a P/E ratio of 17 and a strong return on capital employed of 74.07%. Compared to peers, it maintains a favorable valuation profile and has demonstrated resilience with a year-to-date return of 16.13%, outperforming the S&P 500 over three years."
      },
      {
        "title": "Is Exelixis, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-exelixis-inc-technically-bullish-or-bearish-3651338",
        "imagepath": "",
        "date": "2025-10-28 11:40:55",
        "description": "As of 24 October 2025, the technical trend for Exelixis, Inc. has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by the weekly MACD and moving averages both indicating a bearish outlook. The KST is bearish on the weekly and bullish on the monthly, while the RSI shows a bullish signal on the weekly but no signal on the monthly. Additionally, the Bollinger Bands present a bearish signal on the weekly and a mildly bullish signal on the monthly. \n\nIn terms of performance, Exelixis has outperformed the S&P 500 on a year-to-date basis with a return of 16.28% compared to the S&P 500's 15.47%, and it has significantly outperformed over the past year with a return of 37.74% versus 16.90% for the benchmark. However, it has underperformed in the short term, with a 1-week return of -1.35% compared to the S&P 500's 1.92%...."
      },
      {
        "title": "Exelixis Stock Forms Death Cross, Signaling Potential Bearish Trend Ahead",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/exelixis-stock-forms-death-cross-signaling-potential-bearish-trend-ahead-3648880",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/ExelixisInc_dealthcross_3648880.png",
        "date": "2025-10-27 15:08:28",
        "description": "Exelixis, Inc. has recently encountered a Death Cross, indicating a potential shift in market sentiment. While the stock has outperformed the S&P 500 over the past year, recent weekly performance has declined. Investors are advised to monitor these technical signals as market dynamics evolve in the biotechnology sector."
      },
      {
        "title": "Is Exelixis, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-exelixis-inc-technically-bullish-or-bearish-3647792",
        "imagepath": "",
        "date": "2025-10-27 11:52:02",
        "description": "As of 24 October 2025, the technical trend for Exelixis, Inc. has changed from sideways to mildly bearish. The weekly MACD and KST indicators are both signaling bearish momentum, while the daily moving averages also reflect a mildly bearish stance. The weekly RSI is bullish, but the monthly RSI shows no signal, indicating mixed signals across time frames. Additionally, the Bollinger Bands are bearish on the weekly chart but mildly bullish on the monthly chart. Overall, the technical stance is mildly bearish, driven primarily by the bearish indicators in the MACD, KST, and moving averages. There is no available return data to compare the company's performance against the S&P 500...."
      },
      {
        "title": "Is Exelixis, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-exelixis-inc-technically-bullish-or-bearish-3646323",
        "imagepath": "",
        "date": "2025-10-26 11:26:36",
        "description": "As of 24 October 2025, the technical trend for Exelixis, Inc. has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by weekly MACD and KST indicators both indicating bearishness, alongside a mildly bearish reading from the daily moving averages. The weekly RSI remains bullish, but overall, the bearish signals dominate. \n\nIn terms of performance, Exelixis has outperformed the S&P 500 year-to-date with a return of 16.28% compared to the S&P's 15.47%, and over the past year, it has significantly outperformed with a return of 37.74% versus 16.90%. However, in the shorter term, it has underperformed the S&P 500 over the past week and month...."
      },
      {
        "title": "Exelixis, Inc. Experiences Revision in Its Stock Evaluation Amid Strong Financial Performance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/exelixis-inc-sees-valuation-grade-upgrade-from-fair-to-attractive-3640649",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/ExelixisInc_valuationdot_3640649.png",
        "date": "2025-10-20 15:59:59",
        "description": "Exelixis, Inc. has adjusted its valuation, with a P/E ratio of 17 and a price-to-book value of 5.51. The company demonstrates strong operational performance, reflected in its high ROCE of 74.07% and ROE of 32.08%. Over the past year, Exelixis has outperformed the S&P 500."
      },
      {
        "title": "Exelixis, Inc. Experiences Revision in Its Stock Evaluation Amid Strong Performance Metrics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/exelixis-inc-sees-valuation-grade-upgrade-from-fair-to-attractive-3595372",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/ExelixisInc_valuationdot_3595372.png",
        "date": "2025-10-06 15:51:13",
        "description": "Exelixis, Inc. has recently adjusted its valuation, showcasing a P/E ratio of 17 and a price-to-book value of 5.51. The company demonstrates strong performance metrics, including a 20.39% year-to-date return and a 52.78% return over the past year, highlighting its competitive position in the pharmaceuticals sector."
      },
      {
        "title": "Exelixis, Inc. Experiences Revision in Its Stock Evaluation Amid Strong Market Performance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/exelixis-inc-sees-valuation-grade-upgrade-from-fair-to-attractive-3579788",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/9/ExelixisInc_valuationdot_3579788.png",
        "date": "2025-09-29 15:56:29",
        "description": "Exelixis, Inc. has recently adjusted its valuation, showcasing a P/E ratio of 17 and a price-to-book value of 5.51. The company exhibits strong financial metrics, including a ROCE of 74.07% and a ROE of 32.08%, positioning it favorably against industry peers. Its stock performance has outpaced the S&P 500 year-to-date."
      },
      {
        "title": "Exelixis, Inc. Experiences Revision in Its Stock Evaluation Amid Strong Market Performance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/exelixis-inc-sees-valuation-grade-downgrade-from-attractive-to-fair-3552797",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/9/ExelixisInc_valuationdot_3552797.png",
        "date": "2025-09-22 18:19:52",
        "description": "Exelixis, Inc. has recently adjusted its valuation, showcasing a P/E ratio of 17 and a strong return on capital employed of 74.07%. Compared to peers, it maintains a favorable valuation profile. The company has outperformed the S&P 500 with a year-to-date return of 20.42% and a 49.46% return over the past year."
      }
    ],
    "total": 16,
    "sid": "1153917",
    "stock_news_url": "https://www.marketsmojo.com/news/exelixis-inc-1153917"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Exelixis, Inc. Experiences Revision in Its Stock Evaluation Amid Strong Performance Metrics

2025-11-03 15:38:29

Exelixis, Inc. has recently adjusted its valuation, showcasing a P/E ratio of 17 and a strong return on capital employed of 74.07%. Compared to peers, it maintains a favorable valuation profile and has demonstrated resilience with a year-to-date return of 16.13%, outperforming the S&P 500 over three years.

Is Exelixis, Inc. technically bullish or bearish?

2025-10-28 11:40:55

As of 24 October 2025, the technical trend for Exelixis, Inc. has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by the weekly MACD and moving averages both indicating a bearish outlook. The KST is bearish on the weekly and bullish on the monthly, while the RSI shows a bullish signal on the weekly but no signal on the monthly. Additionally, the Bollinger Bands present a bearish signal on the weekly and a mildly bullish signal on the monthly. In terms of performance, Exelixis has outperformed the S&P 500 on a year-to-date basis with a return of 16.28% compared to the S&P 500's 15.47%, and it has significantly outperformed over the past year with a return of 37.74% versus 16.90% for the benchmark. However, it has underperformed in the short term, with a 1-week return of -1.35% compared to the S&P 500's 1.92%....

Exelixis Stock Forms Death Cross, Signaling Potential Bearish Trend Ahead

2025-10-27 15:08:28

Exelixis, Inc. has recently encountered a Death Cross, indicating a potential shift in market sentiment. While the stock has outperformed the S&P 500 over the past year, recent weekly performance has declined. Investors are advised to monitor these technical signals as market dynamics evolve in the biotechnology sector.

Is Exelixis, Inc. technically bullish or bearish?

2025-10-27 11:52:02

As of 24 October 2025, the technical trend for Exelixis, Inc. has changed from sideways to mildly bearish. The weekly MACD and KST indicators are both signaling bearish momentum, while the daily moving averages also reflect a mildly bearish stance. The weekly RSI is bullish, but the monthly RSI shows no signal, indicating mixed signals across time frames. Additionally, the Bollinger Bands are bearish on the weekly chart but mildly bullish on the monthly chart. Overall, the technical stance is mildly bearish, driven primarily by the bearish indicators in the MACD, KST, and moving averages. There is no available return data to compare the company's performance against the S&P 500....

Is Exelixis, Inc. technically bullish or bearish?

2025-10-26 11:26:36

As of 24 October 2025, the technical trend for Exelixis, Inc. has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by weekly MACD and KST indicators both indicating bearishness, alongside a mildly bearish reading from the daily moving averages. The weekly RSI remains bullish, but overall, the bearish signals dominate. In terms of performance, Exelixis has outperformed the S&P 500 year-to-date with a return of 16.28% compared to the S&P's 15.47%, and over the past year, it has significantly outperformed with a return of 37.74% versus 16.90%. However, in the shorter term, it has underperformed the S&P 500 over the past week and month....

Exelixis, Inc. Experiences Revision in Its Stock Evaluation Amid Strong Financial Performance

2025-10-20 15:59:59

Exelixis, Inc. has adjusted its valuation, with a P/E ratio of 17 and a price-to-book value of 5.51. The company demonstrates strong operational performance, reflected in its high ROCE of 74.07% and ROE of 32.08%. Over the past year, Exelixis has outperformed the S&P 500.

Exelixis, Inc. Experiences Revision in Its Stock Evaluation Amid Strong Performance Metrics

2025-10-06 15:51:13

Exelixis, Inc. has recently adjusted its valuation, showcasing a P/E ratio of 17 and a price-to-book value of 5.51. The company demonstrates strong performance metrics, including a 20.39% year-to-date return and a 52.78% return over the past year, highlighting its competitive position in the pharmaceuticals sector.

Exelixis, Inc. Experiences Revision in Its Stock Evaluation Amid Strong Market Performance

2025-09-29 15:56:29

Exelixis, Inc. has recently adjusted its valuation, showcasing a P/E ratio of 17 and a price-to-book value of 5.51. The company exhibits strong financial metrics, including a ROCE of 74.07% and a ROE of 32.08%, positioning it favorably against industry peers. Its stock performance has outpaced the S&P 500 year-to-date.

Exelixis, Inc. Experiences Revision in Its Stock Evaluation Amid Strong Market Performance

2025-09-22 18:19:52

Exelixis, Inc. has recently adjusted its valuation, showcasing a P/E ratio of 17 and a strong return on capital employed of 74.07%. Compared to peers, it maintains a favorable valuation profile. The company has outperformed the S&P 500 with a year-to-date return of 20.42% and a 49.46% return over the past year.

View All News